SLCO1C1

Across TCGA pan-cancer cohorts, SLCO1C1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SLCO1C1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLCO1C1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLCO1C1 is over-expressed in tumor, although a few such as COAD and KIRP show the opposite, repressed pattern.

KIRC, COAD, and LIHC are the cancer types where SLCO1C1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLCO1C1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.849	<.001	11	view →
COAD	All	IV	−0.388	<.001	11	view →
LIHC	Female	All	+0.226	<.001	9	view →
KIRP	All	All	−0.119	<.001	7	view →
BRCA	All	III,IV	−0.528	<.001	6	view →
LUSC	Male	All	−0.234	<.001	6	view →
BLCA	All	III,IV	−0.142	.021	5	view →
LUAD	Female	III,IV	−0.288	.002	4	view →
STAD	All	II,III,IV	+0.150	.005	4	view →
KICH	All	All	−0.144	.015	4	view →
CHOL	Male	All	+0.243	.001	2	view →
THCA	All	All	+0.181	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SLCO1C1–KIRC

Open the KIRC breakdown →